Rentokil Initial stock steadies after Fitch affirms BBB rating

Published on 09/17/2026 at 17:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rentokil Initial stock slipped to a 12?month low of 322.70 GBX on September 17, 2026 before rebounding intraday. Fitch affirmed the group’s BBB credit rating on September 17, 2026, while the shares trade at a discount to historical book value.

RTO, US76169Y1001, Illustration mit AI erstellt.

Rentokil Initial stock (ISIN US76169Y1001, London ticker RTO) attracted renewed attention on September 17, 2026 as the London-listed shares touched a fresh 12-month low before stabilizing, while Fitch Ratings reaffirmed the company’s BBB credit rating and highlighted its solid market position.

Fitch affirmation and valuation backdrop

According to MarketScreener on September 17, 2026, Fitch affirmed Rentokil Initial’s BBB rating, citing the group’s consolidated market position in pest control and hygiene services and its disciplined financial policy.

As MarketScreener also reports, the latest closing price of Rentokil Initial’s US-listed ADR stood at USD 4.411, with an average analyst price target of USD 6.403, implying upside of about 45.2 percent from that closing level as of mid-September 2026.

A separate equity overview from Saxo on September 17, 2026 notes that Rentokil Initial screens as a UK value stock, trading at a current price-to-book ratio of 2.02 compared with a five-year median price-to-book ratio of 2.91, a discount of 30.8 percent, while the group’s return on equity is around 8.9 percent.

Share price near 12-month low on London Stock Exchange

Rentokil Initial shares are primarily listed on the London Stock Exchange under the ticker RTO, with trading in GBX. An equity snapshot cited by Ad-hoc-news on September 17, 2026 shows the London-listed shares dropping intraday to a new 12-month low of 322.70 GBX before last trading at 328.00 GBX, marginally below a prior close of 328.30 GBX on the same exchange.

The same report from Ad-hoc-news indicates that Rentokil Initial stock has recently traded within a broad intraday range, with another London Stock Exchange snapshot showing the shares at 370.90 GBX, down 1.46 percent from a previous close of 376.40 GBX, on a volume of 10,445,562 shares in mid-September 2026.

In addition, a Cboe Europe quote referenced by MarketScreener shows Rentokil Initial at 328.30 GBX with a modest daily increase of 0.09 percent, though the stock remains lower by 26.53 percent year to date, underscoring the challenging performance of the shares during 2026.

Latest fundamentals and income distribution

Rentokil Initial’s most recent interim results for the half year ended June 30, 2026 are not detailed in the available week-filtered sources, but the company did announce an interim dividend in relation to that reporting period. According to MarketScreener, Rentokil Initial announced an interim dividend for the half year ended June 30, 2026, with payment scheduled for September 21, 2026, providing income to shareholders alongside the capital performance of the stock.

The same corporate news overview on MarketScreener highlights that AlphaValue/Baader Europe recently changed its stance on Rentokil Initial plc from Sell, indicating a shift in analyst perception, and notes governance developments such as the cessation of Richard Leslie Solomons as a director effective August 31, 2026.

For investors assessing Rentokil Initial, the combination of a confirmed BBB rating, a value-style discount to historical price-to-book levels and a year-to-date share price decline of 26.53 percent as of mid-September 2026 suggests that the stock is balancing credit strength against integration concerns and market caution that have weighed on its valuation.

Stock level and ADR perspective

On the London Stock Exchange, Rentokil Initial stock most recently changed hands around 328.00 GBX as of September 17, 2026, close to its fresh 12-month low of 322.70 GBX cited in intraday trading, while year-to-date performance shows a decline of 26.53 percent and valuation metrics point to a roughly 30.8 percent discount versus the company’s five-year median price-to-book ratio.